Remove Cardiovascular Disease Remove Stent Remove Stents
article thumbnail

Philips launches Duo Venous Stent System for Treatment of Symptomatic Venous Outflow Obstruction

DAIC

and an investigator in the VIVID study , which contributed to the device’s FDA approval – successfully used the Duo Venous Stent System for the first time outside of a clinical trial. It is the third most common cardiovascular disease [2]. For long lesions, Duo Extend smoothly overlaps with the Duo Hybrid to extend therapy.

Stent 105
article thumbnail

Elixir Medical PINNACLE I Study of LithiX IVL System Meets Primary Endpoints of Clinical Success

DAIC

Clinical success was defined as optimal stent expansion after final treatment with no in-hospital major adverse cardiovascular event (MACE). stent expansion at Maximum Calcium Site 96.7% interventional cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium. . stent expansion at Maximum Calcium Site 96.7%

Stents 105
article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

FDA Breakthrough Device Designation accelerates the review process for novel technologies that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as CAD, which impacts 7.8% Stent Related Adverse Events greater than 1 Year After PCI. of the U.S. population.

article thumbnail

Association of triglyceride-glucose index with the risk of incident aortic dissection and aneurysm: a large-scale prospective cohort study in UK Biobank

Cardiovascular Diabetology

Triglyceride-glucose (TyG) index is an emerging surrogate indicator of insulin resistance, which has been demonstrated as a risk factor for various cardiovascular diseases including coronary syndrome, in-stent.

Stent 64
article thumbnail

From the Member Sections | Tackling the Polypharmacy Pandemic in CV Care

American College of Cardiology

In a retrospective study of older patients (≥65 years) with cardiovascular disease who were admitted to a cardiology service, the prevalence of polypharmacy (five or more medications) was 95% and 69% for hyper-polypharmacy (≥10 medications), far exceeding that observed in the general population; 77.5% 2021;374:n1493.

article thumbnail

American College of Cardiology Sets Full Range of Education Sessions and Meetings ACC Scientific Session, ACC.24

DAIC

Cardiovascular Update for the Clinician: A Symposium by Valentin Fuster” will offer the latest advances in the treatment of cardiovascular disease and ways to integrate them into daily practice. 24 Education Sessions Symposiums at ACC The “Symposiums at ACC.24”

Education 105
article thumbnail

Physiology Friday #199: High-Intensity Interval Training Reduces Coronary Artery Plaque

Physiologically Speaking

Exercise prevents and reverses cardiovascular disease, but whether high-intensity exercise training (HIIT) is safe and effective for adults after minimally invasive heart surgery is unknown. Exercise is a wonder drug for cardiovascular disease (CVD) prevention and reversal.

Plaque 119